APEX Healthcare ETF

As of 09/27/2022

Ticker APXH	Primary Exchange Cboe BZX Exchange	CUSIP 90214Q659
Inception Date 09/21/2021	Net Assets $6,026,892.85	Shares Outstanding 775,000
Distribution Rate -	NAV $7.78	Closing Market Price $7.77
Premium Discount $-0.01	30 Day Median Bid/Ask Spread 1.20%	FACT SHEET

Investment Overview

Fund Objective

Seeks to provide investment results that correspond generally, before fees and expenses, to the performance of the MarketGrader Global Health Care Leaders Index.

Investment Strategy

The Fund will utilize the MarketGrader Global Health Care Leaders Index for security selection. The Index constituents are selected on the basis of the strength of their fundamentals as measured by the MarketGrader Score (zero to 100). To be eligible for inclusion in the index, a company must have a minimum market capitalization of $500 million at the time of inclusion and a minimum three-month average daily trading volume of $2 million.

Management Team

Investment Partner

Anfield Capital

Anfield Capital is comprised of a team of investment management executives from top-flight institutions. Our highly experienced team of 12 professionals has nearly 300 years of combined experience with the Anfield principals working together as a team for over 25 years.

Fund Managers

Peter Van de Zilver, CFA

Head of PM Analytics and Risk Management

View Profile

David Young, CFA

Founder & Chief Executive Officer

View Profile

Top Holdings as of 09/27/2022

Market Value %	Name	Market Price	Shares Held	Market Value
12.92%	ISHARES GLOBAL HEALTHCARE	$74.91	10,386	$778,015.26
5.88%	VERTEX PHARM	$284.74	1,243	$353,931.82
5.58%	MERCK & CO	$85.84	3,915	$336,063.60
5.28%	REGENERON PHARM	$695.01	457	$317,619.57
4.84%	JOHNSON&JOHNSON	$164.94	1,766	$291,284.04
4.80%	DANAHER CORP	$260.10	1,111	$288,971.10
4.60%	ABBVIE INC	$141.72	1,955	$277,062.60
4.28%	HOYA CORP	$13,590.00	2,748	$257,856.25
4.28%	PFIZER INC	$44.09	5,838	$257,397.42
3.95%	BIONTECH SE	$130.30	1,823	$237,536.90

Market Value: 12.92%
Name: ISHARES GLOBAL HEALTHCARE
Market Price: $74.91
Shares Held: 10,386
Market Value: $778,015.26

Market Value: 5.88%
Name: VERTEX PHARM
Market Price: $284.74
Shares Held: 1,243
Market Value: $353,931.82

Market Value: 5.58%
Name: MERCK & CO
Market Price: $85.84
Shares Held: 3,915
Market Value: $336,063.60

Market Value: 5.28%
Name: REGENERON PHARM
Market Price: $695.01
Shares Held: 457
Market Value: $317,619.57

Market Value: 4.84%
Name: JOHNSON&JOHNSON
Market Price: $164.94
Shares Held: 1,766
Market Value: $291,284.04

Market Value: 4.80%
Name: DANAHER CORP
Market Price: $260.10
Shares Held: 1,111
Market Value: $288,971.10

Market Value: 4.60%
Name: ABBVIE INC
Market Price: $141.72
Shares Held: 1,955
Market Value: $277,062.60

Market Value: 4.28%
Name: HOYA CORP
Market Price: $13,590.00
Shares Held: 2,748
Market Value: $257,856.25

Market Value: 4.28%
Name: PFIZER INC
Market Price: $44.09
Shares Held: 5,838
Market Value: $257,397.42

Market Value: 3.95%
Name: BIONTECH SE
Market Price: $130.30
Shares Held: 1,823
Market Value: $237,536.90

Download All Holdings (.CSV)

Fees

Advisor Fee	Total Expense Ratio	Total Expense Cap
0.75%	1.13%	0.90%

*The Fund’s Adviser has contractually agreed to reduce the Fund’s fees and/or absorb expenses of the Fund until at least November 30, 2022 to ensure that the net annual fund operating expenses will not exceed 0.90%.

Documents

SAI – AUG 17, 2021	Prospectus – AUG 17, 2021	Semi-Annual Report – JAN 31, 2022
Premium/Discount History – JUN 30, 2022	Premium/Discount History – MAR 31, 2022	Fund Holdings – APR 30, 2022
Fund Holdings – OCT 31, 2021

Download All Documents

The median bid-ask spread is calculated by identifying the national best bid and national best offer (“NBBO”) for each fund as of the end of each 10 second interval during each trading day of the last 30 calendar days and dividing the difference between each such bid and offer by the midpoint of the NBBO. The median of those values is identified and that value is expressed as a percentage rounded to the nearest hundredth.

Investors should carefully consider the investment objective, risks, charges and expenses of ETF Funds. This and other information is contained in the prospectus and should be read carefully before investing. For a prospectus please call 866-866-4848 or visit our website at regentsparkfunds. com. Regents Park Funds are distributed by Northern LightsDistributors, LLC, member FINRA/SIPC. Northern Lights Distributors, LLC and Regents Park Funds, LLC are not affiliated.

DISCLOSURE:
IMPORTANT RISK FACTORS

New funds provide a limited history of operations for investors to evaluate. As with all funds, there is a risk that you could lose money through your investment in these Funds. Many factors affect the Fund’s net asset value and performance. There is no guarantee that the investment will achieve its objectives, generate profits or avoid losses. The use of derivative instruments involves risks different from, or possibly greater than, the risks associated with investing directly in securities and other traditional investments. Investing in commodities or futures markets may subject the Fund to greater volatility than investments in traditional securities. These risks include (i) leverage risk (ii) risk of mispricing or improper valuation; and (iii) the risk that changes in the value of the futures contract may not correlate perfectly with the underlying index. There are risks associated with the sale and purchase of call and put options through the Fund’s underlying investments. The use of derivative instruments could lead to potentially greater gains, as well as the potential for greater losses than a fund that does not use derivatives.